Information Provided By: 
Fly News Breaks for February 26, 2020
MEDP
Feb 26, 2020 | 08:16 EDT
SunTrust analyst Sandy Draper raised his price target on Medpace to $100 after its Q4 earnings beat that reflected the quarter's strong net bookings momentum in spite of the higher cancellations. The analyst also notes that the below-consensus FY20 guidance appears to have some "conservatism", but he still keeps his Hold rating, citing his view of limited opportunity for earnings acceleration and further multiple expansion.
News For MEDP From the Last 2 Days
MEDP
Apr 24, 2024 | 07:15 EDT
Guggenheim raised the firm's price target on Medpace to $464 from $453 and keeps a Buy rating on the shares after an EBITDA and EPS beat-and-raise was supported by "generally positive commentary" on the call. Demand remains strong and Medpace has found ways to be more efficient, meeting its demand needs with lower headcount growth, adds the analyst, who notes that management continues to expect the current environment to support accelerating revenue growth in 2025.
